Early erythropoiesis-stimulating agents in preterm or low birth weight infants

Abstract

Early erythropoiesis-stimulating agents in preterm or low birth weight infants.

The Role of Erythropoietin in Preventing Anemia in the Premature Neonate

“…Similar to the results of a recent Cochrane review [15], a reduction in the number of transfusions required has been noted in this study following univariate logistic analysis (OR: 0.21, 95% CI, 0.09-0.48). This, however, contradicts the findings of Doyle J.J. (1997) [9], in which, dissimilar to rhEPO administration starting from the 21st day of life, rhEPO administration starting at less than one week of life was not associated with a decreased number of transfusions.…”

“…Although univariate regression analysis showed only a near-significant association between rhEPO administration and AOP (p = 0.061), multivariate logistic regression analysis revealed a significant relationship between rhEPO therapy and moderate AOP (OR: 0.36, 95% CI, 0.15-0.89), the most common AOP stage found in this study. This near three-fold reduction in moderate AOP incidence is consistent with a large majority of studies that recommend rhEPO administration and point out multiple benefits of this treatment [1,[9][10][11][12][13][14][15][16]18,19]. Furthermore, this warrants future investigation into the effects rhEPO has on different levels of AOP.…”

The Role of Erythropoietin in Preventing Anemia in the Premature Neonate

“…Similar to the results of a recent Cochrane review [15], a reduction in the number of transfusions required has been noted in this study following univariate logistic analysis (OR: 0.21, 95% CI, 0.09-0.48). This, however, contradicts the findings of Doyle J.J. (1997) [9], in which, dissimilar to rhEPO administration starting from the 21st day of life, rhEPO administration starting at less than one week of life was not associated with a decreased number of transfusions.…”

“…Although univariate regression analysis showed only a near-significant association between rhEPO administration and AOP (p = 0.061), multivariate logistic regression analysis revealed a significant relationship between rhEPO therapy and moderate AOP (OR: 0.36, 95% CI, 0.15-0.89), the most common AOP stage found in this study. This near three-fold reduction in moderate AOP incidence is consistent with a large majority of studies that recommend rhEPO administration and point out multiple benefits of this treatment [1,[9][10][11][12][13][14][15][16]18,19]. Furthermore, this warrants future investigation into the effects rhEPO has on different levels of AOP.…”

Erythropoietin Does Not Protect Against Neurodevelopmental Deficits in Early Preterm Infants

“…Specifically, in contrast to previous meta-analyses, treatment with erythropoietin did not result in a higher rate or greater severity of retinopathy of prematurity than placebo. [38][39][40] No other safety concerns arose in this trial -a finding similar to that in the other published studies of erythropoietin for neuroprotection in neonates. 14 In post hoc analyses, we found that the erythropoietin dosing regimen used in PENUT stimulated erythropoiesis, as evidenced by the lower number and lower volume of transfusions and the lower exposure to blood donors in the erythropoietin group than in the placebo group.…”

Prediction Model for Bronchopulmonary Dysplasia in Preterm Newborns

“…Reduced risk of BPD after erythropoietin administration, particularly if initiated within the first four weeks of life, was reported by Rayjada et al [40]. However, no such association has been shown in randomized studies and meta-analyses [41][42][43][44][45]. In our study, there was no statistically significant difference between the BPD and non-BPD groups in relation to erythropoietin administration.…”

The Role of Erythropoietin in Preventing Anemia in the Premature Neonate

“…Similar to the results of a recent Cochrane review [15], a reduction in the number of transfusions required has been noted in this study following univariate logistic analysis (OR: 0.21, 95% CI, 0.09-0.48). This, however, contradicts the findings of Doyle J.J. (1997) [9], in which, dissimilar to rhEPO administration starting from the 21st day of life, rhEPO administration starting at less than one week of life was not associated with a decreased number of transfusions.…”

“…Although univariate regression analysis showed only a near-significant association between rhEPO administration and AOP (p = 0.061), multivariate logistic regression analysis revealed a significant relationship between rhEPO therapy and moderate AOP (OR: 0.36, 95% CI, 0.15-0.89), the most common AOP stage found in this study. This near three-fold reduction in moderate AOP incidence is consistent with a large majority of studies that recommend rhEPO administration and point out multiple benefits of this treatment [1,[9][10][11][12][13][14][15][16]18,19]. Furthermore, this warrants future investigation into the effects rhEPO has on different levels of AOP.…”

Erythropoietin Does Not Protect Against Neurodevelopmental Deficits in Early Preterm Infants

“…Specifically, in contrast to previous meta-analyses, treatment with erythropoietin did not result in a higher rate or greater severity of retinopathy of prematurity than placebo. [38][39][40] No other safety concerns arose in this trial -a finding similar to that in the other published studies of erythropoietin for neuroprotection in neonates. 14 In post hoc analyses, we found that the erythropoietin dosing regimen used in PENUT stimulated erythropoiesis, as evidenced by the lower number and lower volume of transfusions and the lower exposure to blood donors in the erythropoietin group than in the placebo group.…”

Prediction Model for Bronchopulmonary Dysplasia in Preterm Newborns

“…Reduced risk of BPD after erythropoietin administration, particularly if initiated within the first four weeks of life, was reported by Rayjada et al [40]. However, no such association has been shown in randomized studies and meta-analyses [41][42][43][44][45]. In our study, there was no statistically significant difference between the BPD and non-BPD groups in relation to erythropoietin administration.…”

The Role of Erythropoietin in Preventing Anemia in the Premature Neonate

“…Similar to the results of a recent Cochrane review [15], a reduction in the number of transfusions required has been noted in this study following univariate logistic analysis (OR: 0.21, 95% CI, 0.09-0.48). This, however, contradicts the findings of Doyle J.J. (1997) [9], in which, dissimilar to rhEPO administration starting from the 21st day of life, rhEPO administration starting at less than one week of life was not associated with a decreased number of transfusions.…”

“…Although univariate regression analysis showed only a near-significant association between rhEPO administration and AOP (p = 0.061), multivariate logistic regression analysis revealed a significant relationship between rhEPO therapy and moderate AOP (OR: 0.36, 95% CI, 0.15-0.89), the most common AOP stage found in this study. This near three-fold reduction in moderate AOP incidence is consistent with a large majority of studies that recommend rhEPO administration and point out multiple benefits of this treatment [1,[9][10][11][12][13][14][15][16]18,19]. Furthermore, this warrants future investigation into the effects rhEPO has on different levels of AOP.…”

Erythropoietin Does Not Protect Against Neurodevelopmental Deficits in Early Preterm Infants

“…Specifically, in contrast to previous meta-analyses, treatment with erythropoietin did not result in a higher rate or greater severity of retinopathy of prematurity than placebo. [38][39][40] No other safety concerns arose in this trial -a finding similar to that in the other published studies of erythropoietin for neuroprotection in neonates. 14 In post hoc analyses, we found that the erythropoietin dosing regimen used in PENUT stimulated erythropoiesis, as evidenced by the lower number and lower volume of transfusions and the lower exposure to blood donors in the erythropoietin group than in the placebo group.…”

Prediction Model for Bronchopulmonary Dysplasia in Preterm Newborns

“…Reduced risk of BPD after erythropoietin administration, particularly if initiated within the first four weeks of life, was reported by Rayjada et al [40]. However, no such association has been shown in randomized studies and meta-analyses [41][42][43][44][45]. In our study, there was no statistically significant difference between the BPD and non-BPD groups in relation to erythropoietin administration.…”